Promoter holding
64.27%
AP
Aspiro Pharma Limited - Due diligence report
A 360° intelligence report on Aspiropharma: trust score, financial health, credit view, compliance, directors, growth and distress signals -…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Aspiropharma — 360° Intelligence Report
Generated from MCA filings & public records81/100
Trust Score
Low Risk
Aspiropharma is assessed as Low Risk with a Trust Score of 81/100. Aspiropharma is an active public limited indian non-government company incorporated in 2014, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Aspiro Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
85/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Negative operating earnings - debt service depends on external support.
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
Charges position: 15 open (206.91 cr) · 1 satisfied (46.89 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 11 | 48.0 cr |
| State Bank Of Mysore | 1 | 48.0 cr |
| Hdfc Bank Limited | 4 | 48.0 cr |
Compliance Score: 85/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- Delayed payments to MSME suppliers disclosed (17 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| BANDI VAMSIKRISHNA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| REDDY NARSIMHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SRINIVAS DAKARAPU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KRISHNAVENI KURA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMASESHAPPA SIVA PRASAD PANCHANGAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUDERSHAN PALLAP | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MAHESH RAMAPPA KAMALAMMA HASSAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BHASKARREDDY PABBATIREDDY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Dakarapu Srinivas | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 9 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Hetero Labs Limited
Subsidiaries
1
Group entities
1
Capital events
9 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Strivo Pharma Private Limited | Subsidiary Company | 74.00% |
| Hetero Labs Limited | Holding Company | 74.00% |
Key managerial personnel: SRINIVAS DAKARAPU (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 12+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 24% in a year.
15 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 27.82 Lakh.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment67/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 15 open charge(s) of 206.91 cr already registered.
- Compliance record supports lending.
Investor view77/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events10 Oct 2025
Director appointed
BHASKARREDDY PABBATIREDDY (Additional Director)
24 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
18 Nov 2024
Charge satisfied
State Bank Of Mysore
30 Sep 2024
Charge created
Others - 100.00 cr
18 Aug 2024
Director ceased
REDDY NARSIMHA
03 Aug 2024
Director appointed
REDDY NARSIMHA (Director)
10 May 2024
Charge created
Others - 9.00 Lakh
03 Apr 2024
Charge created
Others - 105.00 cr
04 Nov 2023
Charge created
Others - 13.00 Lakh
26 Oct 2023
Charge created
Others - 10.24 Lakh
22 Sep 2023
Director ceased
MAHESH RAMAPPA KAMALAMMA HASSAN
03 Aug 2023
Director appointed
RAMASESHAPPA SIVA PRASAD PANCHANGAM (Director)
07 Jun 2023
Director appointed
MAHESH RAMAPPA KAMALAMMA HASSAN (Director)
01 Jun 2023
Charge created
Others - 18.91 Lakh
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
9 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 9 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Vins Bioproducts Limited | U24110TG1997PLC026437 | Maheswaram, Telangana, India |
| Joganiya Energies Limited | U24292RJ2014PLC045462 | Bhilwara, Rajasthan, India |
| Galaxy Laboratories Private Limited | U85190MH1991PTC062334 | Aurangabad, Maharashtra, India |
| Panchsheel Organics | L24232MP1989PLC005390 | Indore, Madhya Pradesh, India |
| Aceto Chem Private Limited | U24110GJ1993PTC020883 | Surat, Gujarat, India |
| Kwality Chemical Industries Private Limited | U24100MH2010PTC210699 | Navi Mumbai, Maharashtra, India |
| Alben Chemicals Private Limited | U74899DL1995PTC069576 | New Delhi, Delhi, India |
| Shri Ahimsa Naturals Limited | L14101RJ1990PLC005641 | C, Rajasthan, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Aspiropharma before audits and certifications: compliance score 85/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Aspiropharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Aspiropharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Aspiropharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Aspiropharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Aspiropharma an active company?
Aspiropharma has MCA status “Active” with a compliance score of 85/100 (Low Risk).
Is Aspiropharma financially healthy?
Aspiropharma has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Aspiropharma?
Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Aspiropharma?
The ultimate holding entity is Hetero Labs Limited. 9 active director(s) are on record.
Does Aspiropharma have loans or charges against its assets?
15 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Aspiropharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 85/100 (Low Risk).
Is it risky to lend to Aspiropharma?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
